财联社2月20日讯（记者 卢阿峰）近日，歌礼制药-B（01672.HK）对外公布了小分子口服GLP-1R激动剂ASC30美国Ib期多剂量递增研究前两个队列取得积极期中 ...

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...

For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced ...

Abalone Bio, an antibody company measuring large-scale activity data to drive AI-powered discovery of active therapeutics, ...

由歌礼自主研发的ASC30是首款也是唯一一款既可每日一次口服也可每月一次皮下注射的用于治疗肥胖症的小分子GLP-1受体(GLP-1R)激动剂。

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast 2023-2033 Research and Markets Wed, Feb 19, 2025, 10:09 AM 3 min read ...

Harbour BioMed launches Élancé Therapeutics to advance next-generation obesity therapies: Cambridge, Massachusetts Thursday, March 13, 2025, 18:00 Hrs [IST] Harbour BioMed, a gl ...

China’s Harbour BioMed has launched a new biotech to develop bispecific antibodies focused on the holy grail of next-gen ...

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company specializing in novel antibody therapeutics for immunology ...

Dublin, Feb. 19, 2025 (GLOBE NEWSWIRE) -- The "Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast" report has been added to ...